Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why

Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $5.07 and traded as low as $4.83. Aldeyra Therapeutics shares last traded at $4.94, with a volume of 362,371 shares.

Aldeyra Therapeutics Stock Down 1.6 %

The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm has a fifty day moving average of $5.06 and a two-hundred day moving average of $4.81.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). Sell-side analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Institutional Trading of Aldeyra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC boosted its stake in Aldeyra Therapeutics by 7.9% during the second quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock valued at $30,703,000 after buying an additional 682,265 shares during the period. State Street Corp increased its holdings in shares of Aldeyra Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after buying an additional 16,188 shares during the last quarter. Federated Hermes Inc. purchased a new stake in Aldeyra Therapeutics during the second quarter valued at about $1,758,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of Aldeyra Therapeutics by 163.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after buying an additional 295,864 shares in the last quarter. Finally, PFG Investments LLC purchased a new stake in shares of Aldeyra Therapeutics in the 2nd quarter valued at $1,312,000. Institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.